Zydus Cadila gets USFDA nod to market generic antihistamine tablets

The drug will be manufactured at the group's manufacturing facility in Ahmedabad

pharma, medicines, drugs
Press Trust of India
1 min read Last Updated : Jun 24 2020 | 2:52 PM IST

Drug firm Zydus Cadila on Wednesday said it has received nod from the US health regulator to market generic antihistamine Meclizine hydrochloride tablets.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Meclizine hydrochloride tablets in the strengths of 12.5 mg and 25 mg, the company said in a statement.

The drug will be manufactured at the group's manufacturing facility in Ahmedabad, it added.

Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems, Zydus Cadila said.

The group now has 292 approvals and has so far filed over 390 abbreviated new drug applications (ANDA) since the commencement of its filing process, it added.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 367.20per scrip on the BSE, up 0.07 per cent over previous close.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Zydus CadilaUSFDApharmaceutical firms

Next Story